other material
confidence high
sentiment neutral
materiality 0.50
Esperion provides FY2025 expense guidance at J.P. Morgan Conference
Esperion Therapeutics, Inc.
- R&D expenses expected $55M to $65M for FY2025.
- SG&A expenses expected $160M to $170M for FY2025.
- Total operating expenses expected $215M to $235M for FY2025.
- Guidance announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025.